This size range is critical: particles below 100 nm are cleared too rapidly by the renal system, while particles above 300 nm face significant physical barriers to intestinal absorption
Allowing for small, incremental dose adjustments may improve tolerability and optimize long-term treatment outcomes
While enteral administration offers several advantages over other routes of drug delivery in terms of convenience, promoting medication compliance, it faces several obstacles, of which the most widely recognized are inefficient absorption owing to physical barriers and an acidic microenvironment, along with degradation by proteases and the first-pass metabolism in the liver
FDA-registered, GMP-certified facility
Glutathione and phytochelatins responsive key genes involved in HMs detoxification and tolerance in plants
The April 9, 2026, Health Canada public advisory reinforced the warning, naming BPC-157 alongside roughly 40 other peptides flagged for unauthorized sale